Intro Pullout Text Widget

RMD Open

is an open access, peer-reviewed rheumatology journal from BMJ and EULAR, publishing original research on rheumatic and musculoskeletal disorders and connective tissue diseases

Impact Factor: 5.806
Citescore: 7.1
All metrics >>

RMD Open publishes high quality peer-reviewed original research covering the full spectrum of musculoskeletal disorders, rheumatism and connective tissue diseases, including osteoporosis, spine and rehabilitation. Clinical and epidemiological research, basic and translational medicine, interesting clinical cases, and smaller studies that add to the literature are all considered.

It is an online only open access journal that aims to provide rapid publication of research through a continuous publication model. All submitted content is subject to peer review prior to publication. Published work is free to read.

RMD Open is an official journal of EULAR.

Listen to the ARD and RMD Open podcast and subscribe in all podcast platforms, including Apple Podcasts, Google Podcasts, Stitcher and Spotify.

You can keep up with the latest news via Twitter and Facebook.

Editorial team

Current Issue

New Editor-in-Chief: Professor Gerd Burmester

BMJ and EULAR are delighted to announce that Professor Gerd Burmester has been appointed as the new Editor-in-Chief for RMD Open.

Professor Burmester was the Director of the Department of Rheumatology and Clinical Immunology at the Charité Universitätsmedizin Berlin until very recently and is now a Senior Professor at this institution. He is a former President of EULAR. Since 2017 he has been President of the Board of Trustees of the FOREUM Foundation for Research in Rheumatology.

Professor Burmester has been an active supporter of RMD Open since its inception and we're excited that he has agreed to take the journal forward into its next stage of development.

Intro Pullout Text Widget

RMD Open

New Editor-in-Chief: Professor Gerd Burmester

Latest Articles

Rheumatoid arthritis:

Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis

Rheumatoid arthritis:

Prevalence of sarcopenia in patients with rheumatoid arthritis using the revised EWGSOP2 and the FNIH definition

Rheumatoid arthritis:

Overtreatment in rheumatoid arthritis: are there reasons for concern?

Psoriatic arthritis:

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis

Autoimmunity:

Human epididymis protein 4 (HE4) is a novel biomarker for fibrosis in IgG4-related disease and can predict poor prognosis

Why submit to RMD Open?

RMD Open

Most Read Articles

Miscellaneous:

Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs

Rheumatoid arthritis:

After 25 years of drug development, do we know JAK?

Spondyloarthritis:

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension

Vasculitis:

Immune checkpoint inhibitors as potential triggers for ANCA vasculitis

Infections:

SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry

COVID-19 Content

INFECTIONS:

Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity

CONNECTIVE TISSUE DISEASES:

Outcome of COVID-19 in patients with rheumatic and inflammatory diseases treated with mycophenolic acid: data from the French RMD COVID-19 cohort

SPONDYLOARTHRITIS:

Impact of the COVID-19 pandemic on work productivity in patients with spondyloarthritis: results from the Dutch SpA-Net registry

INFECTIONS:

Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination

INFECTIONS:

Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey